Bioconjugation of the gold drug auranofin to human ferritin yields a potent cytotoxin-Reference-Cited by-同舟云学术

Bioconjugation of the gold drug auranofin to human ferritin yields a potent cytotoxin

Published:2023-09 Issue: Volume:87 Page:104822
ISSN:1773-2247
Container-title:Journal of Drug Delivery Science and Technology
language:en
Short-container-title:Journal of Drug Delivery Science and Technology

Author:

Cosottini Lucrezia,Massai Lara^ORCID,Ghini Veronica,Zineddu Stefano^ORCID,Geri Andrea,Mannelli Michele,Ciambellotti Silvia^ORCID,Severi Mirko^ORCID,Gamberi Tania,Messori Luigi,Turano Paola

Funder

AIRC

Fondazione Cassa di Risparmio di Firenze

Associazione Italiana per la Ricerca sul Cancro

Publisher

Elsevier BV

Subject

Pharmaceutical Science

Reference53 articles.

1. Gold compounds as anticancer agents: chemistry, cellular pharmacology, and preclinical studies: gold compounds as anticancer agents;Nobili;Med. Res. Rev.,2010

2. Gold-based therapeutic agents;Shaw;Chem. Rev.,1999

3. Auranofin: repurposing an old drug for a golden new age;Roder;Drugs R,2015

4. Benzimidazol-2-ylidene gold(I) complexes are thioredoxin reductase inhibitors with multiple antitumor properties;Rubbiani;J. Med. Chem.,2010

5. In-vitro and in-vivo investigations into the carbene-gold anticancer drug candidates NHC*-Au-SCSNMe2 and NHC*-Au-S-GLUC against advanced prostate cancer PC3;Walther;Anti Cancer Drugs,2020

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells;Angewandte Chemie International Edition;2024-08-19

2. Unlocking the Power of Human Ferritin: Enhanced Drug Delivery of Aurothiomalate in A2780 Ovarian Cancer Cells;Angewandte Chemie;2024-08-19

3. Cell Metabolomics to Guide the Design of Metal-Based Compounds;Inorganics;2024-06-15

4. Strategies for the design of analogs of auranofin endowed with anticancer potential;Expert Opinion on Drug Discovery;2024-05-27

5. NMR Metabolomics of Primary Ovarian Cancer Cells in Comparison to Established Cisplatin-Resistant and -Sensitive Cell Lines;Cells;2024-04-09